natgillin/translations-raw huggingface dataset:
10 g 
Peroralna uporaba 10 g
1 mg/kg/day If your baby is less than 4 weeks old, talk to your doctor or pharmacist before giving them this medicine, in particular if the baby is given other medicines that contain propylene glycol or alcohol. 
1 mg/kg/dan Če je vaš otrok mlajši od 4 tednov, se pred dajanjem zdravila posvetujte z zdravnikom ali farmacevtom.
If you have a kidney disease, talk to your doctor before you receive this medicine. 
Če imate bolezen ledvic, se pred prejetjem tega zdravila posvetujte z zdravnikom.
Lilial 
Kalij
Contains x g galactose per dose. 
Vsebuje x g galaktoze na odmerek.
Arachis oil (peanut oil) 
Arašidovo olje (olje zemeljskega oreška)
Potassium metabisulphite (E 224) 
Kalijev metabisulfit (E 224) Kalijev hidrogensulfit (E
May be irritant to the skin. 
Lahko draži kožo.
3 mg B/day* Do not give to a child less than 12 years old as this medicine contains boron and may impair fertility in the future. 
Borova kislina (in borati) 09/10/2017 Vse poti uporabe 3 mg B/dan* Ne dajajte otrokom, mlajšim od 12 let, ker zdravilo vsebuje bor, ki lahko v prihodnosti vpliva na plodnost.
Organic mercury compounds e.g.: 
Organske živosrebrove spojine npr.:
7 mg B/day* Do not give to a child less than 18 years old as this medicine contains boron and may impair fertility in the future. 
Borova kislina (in borati) 09/10/2017 Vse poti uporabe 7 mg B/dan* Ne dajajte otrokom, mlajšim od 18 let, ker zdravilo vsebuje bor, ki lahko prihodnosti vpliva na plodnost.
A detailed history with regard to HFI symptoms has to be taken of each patient prior to being given this medicinal product. 
Pred dajanjem zdravila mora biti pri bolniku narejena podrobna anamneza, povezana s simptomi dedne intolerance za frukozo.
Methyl heptine carbonate 
Makrogolglicerol hidroksistearat
Sodium ethyl phydroxybenzoate (E 215) Propyl p-hydroxybenzoate Sodium propyl phydroxybenzoate Methyl p-hydroxybenzoate (E 218) 
Propilparahidroksibenzoat Natrijev propilparahidroksibenzoat Metilparahidroksibenzoat (E
SmPC proposal: Patients with rare glucose-galactose malabsorption should not take this medicine. 
Predlog SmPC: Bolniki z redko malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila.
1 mg B/day* Do not give to a child less than 2 years old as this medicine contains boron and may impair fertility in the future. 
Borova kislina (in borati) 09/10/2017 Vse poti uporabe 1 mg B/dan* Ne dajajte otrokom, mlajšim od 2 let, ker zdravilo vsebuje bor, ki lahko v prihodnosti vpliva na plodnost.
Potassium bisulphite (E 
Natrijev metabisulfit (E
09/10/2017 All 
09/10/2017 Vse poti uporabe Nič
Calorific value 2.4 kcal/g xylitol. 
Kalorična vrednost je 2,4 kcal/g ksilitola.
50 mg/kg/day Propylene glycol may cause skin irritation. 
09/10/2017 Dermalna uporaba 50 mg/kg/dan Propilenglikol lahko povzroči draženje kože.
500 mg/kg/day Propylene glycol may cause skin irritation. 
09/10/2017 Dermalna uporaba 500 mg/kg/dan Propilenglikol lahko povzroči draženje kože.
Farnesol 
Lanolin
20 mg/kg/day This medicine contains x mg cyclodextrin(s) in each <dosage unit><unit volume> <which is equivalent to x mg/<weight><volume>>. 
09/10/2017 Vse poti uporabe 20 mg/kg/dan To zdravilo vsebuje x mg ciklodekstrina (ciklodekstrinov) v <enota odmerka><enota volumna><, kar je enako x mg/<masa><volumen>>.
1 mg/kg/day This medicine contains x mg propylene glycol in each <dosage unit><unit volume> <which is equivalent to x mg/<weight><volume>>. 
09/10/2017 Vse poti uporabe 1 mg/kg/dan To zdravilo vsebuje x mg propilenglikola v <enota odmerka><enota volumna><, kar je enako x mg/<masa><volumen>>.
Hydroxymethylpentyl-cyclohexenecarboxaldehyde Isoeugenol 
D-limonen evgenol farnezol geraniol heksilcinamaldehid hidroksicitronelal hidroksimetilpentilcikloheksenkarboksaldehid izoevgenol lilijal linalol metilheptinkarbonat hrastov mah drevesni mah
This medicine contains x mg of alcohol (ethanol) in each <dosage unit><unit volume> <which is equivalent to x mg/<weight><volume>><(y% w/<w><v>)>. 
To zdravilo vsebuje x mg alkohola (etanola) v eni/enem <enota odmerka><enota volumna> <, kar ustreza x mg/<masa><volumen>><(y % m/<m><v>)>.
This medicine contains x mg <benzoic acid/benzoate salt> in each <dosage unit><unit volume> <which is equivalent to x mg/<weight><volume>>. 
To zdravilo vsebuje x mg <benzojske kisline/benzoata> v <enota odmerka><enota volumna><, kar je enako x mg/<masa><volumen>>.
Butylated hydroxytoluene (E 321) 
Butilhidroksitoluen (E
SmPC proposal: Patients with rare hereditary problems of fructose intolerance or glucose-galactose malabsorption should not take this medicine. 
Predlog SmPC: Bolniki z redko dedno intoleranco za fruktozo ali malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila.
SmPC proposal: Patients with rare hereditary problems of galactose intolerance e.g. galactosaemia<, or glucosegalactose malabsorption> should not take this medicine. 
Predlog SmPC: Bolniki z redko dedno intoleranco za galaktozo, kot je npr. galaktozemija, <ali malabsorpcijo glukoze/galaktoze,> ne smejo jemati tega zdravila.
This medicine contains x mg benzyl alcohol in each <dosage unit><unit volume> <which is equivalent to x mg/<weight><volume>>. 
To zdravilo vsebuje x mg benzilalkohola v <enota odmerka><enota volumna><, kar je enako x mg/<masa><volumen>>.
Anisyl alcohol 
Stearilalkohol
This medicine contains x mg benzalkonium chloride in each <dosage unit><unit volume> <which is equivalent to x mg/<weight><volume>>. 
To zdravilo vsebuje x mg benzalkonijevega klorida v <enota odmerka><enota volumna><, kar je enako x mg/<masa><volumen>>.
This medicine contains x mg aspartame in each <dosage unit><unit volume> <which is equivalent to x mg/<weight><volume>>. 
To zdravilo vsebuje x mg aspartama v <enota odmerka><enota volumna><, kar je enako x mg/<masa><volumen>>.
This medicine contains x mg sorbitol in each <dosage unit><unit volume> <which is equivalent to x mg/<weight><volume>>. 
To zdravilo vsebuje x mg sorbitola v <enota odmerka><enota volumna><, kar je enako x mg/<masa><volumen>>.
SmPC proposal: Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. 
Predlog SmPC: Bolniki z redko dedno intoleranco za fruktozo, malabsorpcijo glukoze/galaktoze ali pomanjkanjem saharoza-izomaltaze ne smejo jemati tega zdravila.
09/10/2017 Cutaneous 
09/10/2017 Okularna uporaba Nič
This medicine contains x mg fructose in each <dosage unit><unit volume> <which is equivalent to x mg/<weight><volume>>. 
To zdravilo vsebuje x mg fruktoze v <enota odmerka><enota volumna><, kar je enako x mg/<masa><volumen>>.
This medicine contains x mg phosphates in each <dosage unit><unit volume> <which is equivalent to x mg/<weight><volume>>. 
To zdravilo vsebuje x mg fosfatov v <enota odmerka><enota volumna><, kar je enako x mg/<masa><volumen>>.
Benzalkonium chloride 09/10/2017 All 
Benzalkonijev klorid 09/10/2017 Vse poti uporabe Nič
SmPC proposal: Patients with rare hereditary problems of fructose intolerance, galactose intolerance, galactosaemia or glucose-galactose malabsorption should not take this medicine. 
Predlog SmPC: Bolniki z redko dedno intoleranco za fruktozo, intoleranco za galaktozo, kot je npr. galaktozemija, ali malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila.
This medicine contains x mg phenylalanine in each <dosage unit><unit volume> <which is equivalent to x mg/<weight><volume>>. 
To zdravilo vsebuje x mg fenilalanina v <enota odmerka><enota volumna><, kar je enako x mg/<masa><volumen>>.
SmPC proposal: Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucosegalactose malabsorption should not take this medicine. 
Predlog SmPC: Bolniki z redko dedno intoleranco za galaktozo, odsotnostjo encima laktaze ali malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila.
This medicine contains x mg sodium laurilsulfate in each <dosage unit><unit volume> <which is equivalent to x mg/<weight><volume>>. 
To zdravilo vsebuje x mg natrijevega lavrilsulfata v <enota odmerka><enota volumna><, kar je enako x mg/<masa><volumen>>.
Benzalkonium chloride 09/10/2017 Cutaneous 
Benzalkonijev klorid 09/10/2017 Okularna uporaba Nič
Citral 
Klorokrezol
It is used specifically in adults with advanced cancer in the following situations: 
Zlasti se uporablja pri odraslih z napredovalim rakom v naslednjih pogojih:
The tablets should be taken without food and no food should be eaten for at least 3 hours before and 1 hour after taking the tablets. 
Tablete je treba jemati brez hrane, pri čemer se hrana ne sme zaužiti najmanj tri ure pred zaužitjem tablet in eno uro po njem.
Giotrif is available as tablets (20, 30, 40 and 50 mg) and is only available with a prescription. 
Zdravilo Giotrif je na voljo v obliki tablet (20, 30, 40 in 50 mg) in se izdaja le na recept.
Treatment should continue for as long as possible, until the disease worsens or the side effects become too severe. 
Zdravljenje mora trajati čim dlje, dokler se bolezen ne poslabša ali dokler neželeni učinki ne postanejo prehudi.
The European Commission granted a marketing authorisation valid throughout the European Union for Giotrif on 25 September 2013. 
Evropska komisija je dovoljenje za promet z zdravilom Giotrif, veljavno po vsej Evropski uniji, izdala 25. septembra 2013.
The full EPAR for Giotrif can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Giotrif je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This is a summary of the European public assessment report (EPAR) for Giotrif. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Giotrif.
What measures are being taken to ensure the safe and effective use of Giotrif? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Giotrif?
The most common side effects with Giotrif (which may affect more than 1 in 10 people) are paronychia (nail bed infection), reduced appetite, epistaxis (nosebleeds), diarrhoea, nausea (feeling sick), vomiting, stomatitis (inflammation of the lining of the mouth), rash, acneiform dermatitis (acne-like skin conditions), pruritus (itching), and dry skin. 
Najpogostejši neželeni učinki zdravila Giotrif (ki lahko prizadenejo več kot 1 osebo od 10) so paronihija (okužba nohtnega ležišča), zmanjšan tek, epistaksa (krvavitve iz nosu), driska, navzeja (slabost), bruhanje, stomatitis (vnetje ustne sluznice), izpuščaj, akneiformni dermatitis (aknam podobna kožna bolezen), pruritus (srbenje) in suha koža.
Lung cancer cells with mutated EGFR proteins are particularly sensitive to afatinib. 
Celice pljučnega raka z mutiranimi beljakovinami EGFR so še posebno občutljive za afatinib.
Other information about Giotrif 
Druge informacije o zdravilu Giotrif
This means that it blocks the action of a group of proteins known as ‘ErbB family' which are found on the surface of cancer cells and are involved in stimulating the cells to divide. 
To pomeni, da zavira delovanje posebne družine beljakovin, imenovane „družina ErbB“, ki so na površini rakavih celic in sodelujejo pri spodbujanju nenadzorovane delitve celic.
By blocking these proteins, afatinib helps to control cell division and thereby slows down the growth and spread of the non-small cell lung cancer. 
Afatinib z zaviranjem teh beljakovin pomaga nadzorovati delitev celic in posledično upočasni rast in širjenje nedrobnoceličnega pljučnega raka.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Giotrif outweigh its risks and recommended that it be granted marketing authorisation in the EU. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Giotrif večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
A risk management plan has been developed to ensure that Giotrif is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Giotrif je bil pripravljen načrt obvladovanja tveganj.
In addition, the side effects of the medicine were considered to be manageable and similar to those seen with medicines of the same class. 
Prav tako je menil, da so neželeni učinki zdravila obvladljivi in podobni učinkom, opaženim pri drugih zdravilih iz iste skupine.
Treatment with Giotrif should be started and supervised by a doctor experienced in the use of cancer medicines. 
Zdravljenje z zdravilom Giotrif mora uvesti in nadzorovati zdravnik, ki ima izkušnje z uporabo zdravil za zdravljenje raka.
It is not intended to provide practical advice on how to use Giotrif. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
The recommended dose is 40 mg once daily but this may be increased to up to 50 mg per day in patients who tolerate the 40 mg dose, or interrupted and reduced in patients experiencing side effects. 
Priporočeni odmerek je 40 mg enkrat na dan, ta pa se lahko pri bolnikih, ki 40-miligramski odmerek dobro prenašajo, poveča do največ 50 mg, pri bolnikih, pri katerih se pojavijo neželeni učinki, pa je treba zdravljenje prekiniti in zmanjšati odmerek.
• when the cancer is of a squamous cell type (from cells of the lining of the lungs) and has worsened despite treatment with platinum-based chemotherapy. 
• če gre za raka skvamoznih celic (na pljučni mreni), ki se je poslabšal kljub zdravljenju s kemoterapijo na osnovi platine.
For the full list of all side effects and restrictions with Giotrif, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Giotrif glejte navodilo za uporabo.
For more information about treatment with Giotrif, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Giotrif preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The active substance in Giotrif, afatinib, is an ErbB family blocker. 
Zdravilna učinkovina v zdravilu Giotrif, afatinib, je zaviralec družine ErbB.
What are the risks associated with Giotrif? 
Kakšna tveganja so povezana z zdravilom Giotrif?
Giotrif has been shown to significantly delay disease progression in patients with non-small cell lung cancer. 
Dokazano je bilo, da zdravilo Giotrif znatno upočasni napredovanje bolezni pri bolnikih z nedrobnoceličnim pljučnim rakom.
What benefits of Giotrif have been shown in studies? 
Kakšne koristi je zdravilo Giotrif izkazalo v študijah?
What is Giotrif and what is it used for? 
Kaj je zdravilo Giotrif in za kaj se uporablja?
In a second study in 795 patients with the squamous cell cancer type, patients treated with Giotrif lived on average for 2.6 months without their disease worsening compared with 1.9 months for patients treated with another cancer medicine, erlotinib. 
V drugi študiji s 795 bolniki z rakom skvamoznih celic so bolniki, zdravljeni z zdravilom Giotrif, v povprečju živeli 2,6 meseca brez poslabšanja bolezni, v primerjavi z 1,9 meseca pri bolnikih, ki so prejemali drugo vrsto zdravila za zdravljenje raka, erlotinib.
Why is Giotrif approved? 
Zakaj je bilo zdravilo Giotrif odobreno?
In a main study in 345 patients with tumours that have mutated EGFR genes, patients treated with Giotrif lived on average for 11 months without their disease getting worse compared with 7 months for patients who were treated with two other cancer medicines, pemetrexed and cisplatin. 
V eni glavni študiji s 345 bolniki s tumorji, ki so imeli mutirane gene za EGFR, so bolniki, zdravljeni z zdravilom Giotrif, v povprečju živeli 11 mesecev brez poslabšanja bolezni, bolniki, ki so jih zdravili z dvema drugima zdraviloma proti raku, pemetreksedom in cisplatinom, pa sedem mesecev.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Giotrif, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu z njim so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
• when the cancer has a mutation in the gene for a protein called EGFR and has not been previously treated with tyrosine kinase inhibitor medicines. 
• če ima rak mutacijo gena za beljakovino, imenovano EGFR, in bolnik še ni bil zdravljen z zaviralci tirozin-kinaze;
The CHMP considered that in patients treated with Giotrif the improvement in progression-free survival (how long they lived without the disease getting worse) was a meaningful benefit for patients. 
Menil je, da je bilo za bolnike, ki so bili zdravljeni z zdravilom Giotrif, podaljšanje preživetja brez napredovanja bolezni (kako dolgo so bolniki živeli, ne da bi se bolezen poslabšala) pomembna korist zdravljenja.
EGFR proteins are part of the ErbB family. 
V družino ErbB spadajo tudi beljakovine EGFR.
For practical information about using Giotrif, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Giotrif naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Giotrif is a medicine used to treat a type of lung cancer known as non-small cell lung cancer. 
Uporablja se za zdravljenje vrste pljučnega raka, ki ga imenujemo nedrobnocelični pljučni rak.
How is Giotrif used? 
Kako se zdravilo Giotrif uporablja?
How does Giotrif work? 
Kako zdravilo Giotrif deluje?
Giotrif contains the active substance afatinib. 
Vsebuje zdravilno učinkovino afatinib.
This summary was last updated in April 2012. 
Povzetek je bil nazadnje posodobljen v april 2012.
EMA/CVMP/19896/2007 EMEA/V/C/000082 
EMA/67111/2007 EMEA/V/C/000082
Avoid contact with eyes and skin. 
Izogibajte se stiku z očmi in kožo.
The European Commission granted a marketing authorisation valid throughout the European Union for Previcox on 13 September 2004. 
Evropska komisija je dovoljenje za promet z zdravilom Previcox, veljavno po vsej Evropski uniji, odobrila dne 13. septembra 2004.
Horse: 
Konji:
Other information about Previcox: 
Druge informacije o zdravilu Previcox:
Dog: 
Psi:
Wash hands after use of the product. 
Po uporabi tega izdelka si umijte roke.
The dose, duration of treatment and frequency will depend on the weight and type of animal and condition to be treated. 
Odmerek, trajanje in pogostost zdravljenja so odvisni od teže in vrste živali ter stanja, ki ga zdravite.
These reactions are generally of a transitory nature and are reversible when the treatment is stopped. 
Te reakcije so v glavnem prehodne narave in izginejo po prekinitvi zdravljenja.
What benefit has Previcox shown during the studies? 
Kakšne koristi je zdravilo Previcox izkazalo med raziskavami?
After the last day of treatment with Previcox, horses should not be slaughtered for 26 days (when treated with the oral paste). 
Po zadnjemu dnevu zdravljenja z zdravilom Previcox konjev ne smete zaklati še 26 dni (če jih zdravite z oralno pasto).
Previcox has been studied in laboratory animals, as well as in dogs and horses that were treated in various veterinary practices/clinics across Europe (“clinical studies”). 
Zdravilo Previcox so raziskovali pri laboratorijskih živalih, kot tudi psih in konjih, ki so jih zdravili v različnih veterinarskih ustanovah in klinikah po vsej Evropi (klinične raziskave).
The Committee for Medicinal Products for Veterinary Use (CVMP) decided that the benefits of Previcox are greater than any risks of treatment and they recommended that Previcox should be given a marketing authorisation. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je mnenja, da so koristi zdravila Previcox večje od vseh tveganj zdravljenja, in priporoča odobritev dovoljenja za promet z zdravilom Previcox.
Previcox is presented as chewable tablets for dogs (57 mg and 227 mg) and as an oral paste for horses (8.2 mg/g). 
Zdravilo Previcox je na voljo v obliki žvečljivih tablet za pse (57 mg in 227 mg), odobreno pa je tudi kot oralna pasta za konje (8,2 mg/g).
Why has Previcox been approved? 
Zakaj je bilo zdravilo Previcox odobreno?
Return halved tablets to the blister and keep out of the reach of children. 
Razpolovljene tablete vrnite v pretisni omot in shranjujte izven pogleda in dosega otrok.
What is the risk associated with Previcox? 
Kakšna tveganja so povezana z zdravilom Previcox?
The product was shown to be comparable to other reference products (carprofen and meloxicam, respectively). 
Z raziskavami so uspeli pokazati, da je izdelek primerljiv z drugimi referenčnimi izdelki (karprofen in meloksikam).
Firocoxib blocks the enzyme (cyclo-oxygenase) that is involved in the production of prostaglandins. 
Firokoksib blokira encim (ciklooksigenaza), ki sodeluje pri tvorjenju prostaglandinov.
The withdrawal period is the time allowed after administration of the medicine and before the animal can be slaughtered and the meat or milk used for human consumption. 
Karenca je časovno obdobje, ki mora preteči po uporabi zdravila, preden se lahko žival zakolje ter se meso ali mleko uporabi za prehrano ljudi.
Administration of the product in accordance with the recommended dosing schedule for a period of up to 90 days resulted in an improvement in lameness score in dogs with established osteoarthritis. 
Uporaba izdelka v skladu s priporočeno shemo odmerjanja v trajanju do 90 dni je izboljšala oceno šepavosti pri psih z ugotovljeno osteoartritisom.
The use of Previcox is not permitted in mares producing milk for human consumption. 
Uporaba zdravila Previcox ni dovoljena pri kobilah, ki proizvajajo mleko za prehrano ljudi.
Previcox chewable tablets for dogs were studied in two large European field studies in dogs for a period of up to 90 days. 
Zdravilo Previcox v obliki žvečljivih tablet za pse so raziskovali pri psih v dveh velikih evropskih raziskavah na terenu do 90 dni.
Previcox must not be administered with corticosteroids or other NSAIDs. 
Zdravila Previcox ne smete dajati skupaj s kortikosteroidi ali drugimi NSPVZ-ji.
As the prostaglandins are substances that trigger pain, inflammation and fever, Previcox, therefore, reduces those responses. 
Ker so prostaglandini snovi, ki pomagajo sprožiti bolečino, nabiranje tekočine in vnetje, zdravilo Previcox zmanjša prisotnost teh odzivov.
What is Previcox used for? 
Za kaj se zdravilo Previcox uporablja?
Women of child-bearing age should avoid contact with, or wear disposable gloves, when administering the product. 
Nosečnice naj se izogibajo stika z zdravilom, oziroma naj pri dajanju zdravila nosijo zaščitne rokavice.
Previcox contains firocoxib, which belongs to a class of medicines called non-steroidal antiinflammatory drugs (NSAIDs) belonging to the Coxib group, which acts by selective inhibition of cyclooxygenase-2 (COX-2). 
Zdravilo Previcox vsebuje zdravilno učinkovino firokoksib, ki spada v razred nesteroidnih protivnetnih učinkovin (NSPVZ), natančneje v skupino koksibov, ki selektivno zavirajo encim ciklooksigenaza-2 (COX-2).
Previcox oral paste administered once daily for 14 days at a dose of 0.1 mg/kg improved clinical scores for lameness and soft tissue injuries in horses and also helped alleviate pain and inflammation associated with osteoarthritis in horses. 
Zdravilo Previcox v obliki oralne paste enkrat dnevno v času 14 dni in pri odmerku 0,1 mg/kg je pri konjih izboljšalo klinične ocene šepavosti in poškodb mehkih tkiv ter pomagalo lajšati bolečine in vnetja, povezana z osteoartritisom.
In case of accidental ingestion, it is necessary to seek medical advice immediately and show the package leaflet or the label to the physician. 
V primeru nenamernega zaužitja se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali nalepko na zunanji ovojnini.
For details, please see the Package Leaflet. 
Za podrobnosti si oglejte Navodilo za uporabo.